You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Colorcon
Harvard Business School
Dow
McKinsey

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Ozanimod hydrochloride - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for ozanimod hydrochloride and what is the scope of freedom to operate?

Ozanimod hydrochloride is the generic ingredient in one branded drug marketed by Celgene Intl and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ozanimod hydrochloride has twenty-seven patent family members in twenty countries.

One supplier is listed for this compound.

Summary for ozanimod hydrochloride
International Patents:27
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 16
DailyMed Link:ozanimod hydrochloride at DailyMed
Recent Clinical Trials for ozanimod hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bristol-Myers SquibbPhase 2
François LellouchePhase 2
CelgenePhase 2/Phase 3

See all ozanimod hydrochloride clinical trials

US Patents and Regulatory Information for ozanimod hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene Intl ZEPOSIA ozanimod hydrochloride CAPSULE;ORAL 209899-003 Mar 25, 2020 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Celgene Intl ZEPOSIA ozanimod hydrochloride CAPSULE;ORAL 209899-001 Mar 25, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
Celgene Intl ZEPOSIA ozanimod hydrochloride CAPSULE;ORAL 209899-003 Mar 25, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Celgene Intl ZEPOSIA ozanimod hydrochloride CAPSULE;ORAL 209899-002 Mar 25, 2020 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Celgene Intl ZEPOSIA ozanimod hydrochloride CAPSULE;ORAL 209899-001 Mar 25, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
Celgene Intl ZEPOSIA ozanimod hydrochloride CAPSULE;ORAL 209899-003 Mar 25, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Colorcon
Express Scripts
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.